These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 19546056)

  • 1. Continuous subcutaneous pramlintide infusion therapy in patients with type 1 diabetes: observations from a pilot study.
    Huffman DM; McLean GW; Seagrove MA
    Endocr Pract; 2009; 15(7):689-95. PubMed ID: 19546056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pramlintide improved measures of glycemic control and body weight in patients with type 1 diabetes mellitus undergoing continuous subcutaneous insulin infusion therapy.
    Herrmann K; Frias JP; Edelman SV; Lutz K; Shan K; Chen S; Maggs D; Kolterman OG
    Postgrad Med; 2013 May; 125(3):136-44. PubMed ID: 23748514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Minimal reduction in insulin dosage with pramlintide therapy when pretreatment near-normal glycemia is established and square-wave meal bolus is used.
    King AB
    Endocr Pract; 2009 Apr; 15(3):229-33. PubMed ID: 19364691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized comparison of pramlintide or mealtime insulin added to basal insulin treatment for patients with type 2 diabetes.
    Riddle M; Pencek R; Charenkavanich S; Lutz K; Wilhelm K; Porter L
    Diabetes Care; 2009 Sep; 32(9):1577-82. PubMed ID: 19502544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes.
    Edelman S; Garg S; Frias J; Maggs D; Wang Y; Zhang B; Strobel S; Lutz K; Kolterman O
    Diabetes Care; 2006 Oct; 29(10):2189-95. PubMed ID: 17003291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps.
    Levetan C; Want LL; Weyer C; Strobel SA; Crean J; Wang Y; Maggs DG; Kolterman OG; Chandran M; Mudaliar SR; Henry RR
    Diabetes Care; 2003 Jan; 26(1):1-8. PubMed ID: 12502651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin.
    Riddle M; Frias J; Zhang B; Maier H; Brown C; Lutz K; Kolterman O
    Diabetes Care; 2007 Nov; 30(11):2794-9. PubMed ID: 17698615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the post-meal glucose response to different insulin bolus waveforms in insulin pump- and pre-meal pramlintide-treated type 1 diabetes patients.
    King AB
    Diabetes Technol Ther; 2010 Feb; 12(2):105-8. PubMed ID: 20105039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of pramlintide as an adjunct to basal insulin on markers of cardiovascular risk in patients with type 2 diabetes.
    Wysham C; Lush C; Zhang B; Maier H; Wilhelm K
    Curr Med Res Opin; 2008 Jan; 24(1):79-85. PubMed ID: 18031595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pramlintide acetate injection for the treatment of type 1 and type 2 diabetes mellitus.
    Singh-Franco D; Robles G; Gazze D
    Clin Ther; 2007 Apr; 29(4):535-62. PubMed ID: 17617279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of prandial pramlintide in the treatment of adolescents with type 1 diabetes.
    Rodriguez LM; Mason KJ; Haymond MW; Heptulla RA
    Pediatr Res; 2007 Dec; 62(6):746-9. PubMed ID: 17957149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial.
    Hollander PA; Levy P; Fineman MS; Maggs DG; Shen LZ; Strobel SA; Weyer C; Kolterman OG
    Diabetes Care; 2003 Mar; 26(3):784-90. PubMed ID: 12610038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pramlintide in the treatment of type 1 and type 2 diabetes mellitus.
    Ryan GJ; Jobe LJ; Martin R
    Clin Ther; 2005 Oct; 27(10):1500-12. PubMed ID: 16330288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study.
    Weyer C; Gottlieb A; Kim DD; Lutz K; Schwartz S; Gutierrez M; Wang Y; Ruggles JA; Kolterman OG; Maggs DG
    Diabetes Care; 2003 Nov; 26(11):3074-9. PubMed ID: 14578242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial.
    Ratner RE; Dickey R; Fineman M; Maggs DG; Shen L; Strobel SA; Weyer C; Kolterman OG
    Diabet Med; 2004 Nov; 21(11):1204-12. PubMed ID: 15498087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of pramlintide on A1C and body weight in insulin-treated African Americans and Hispanics with type 2 diabetes: a pooled post hoc analysis.
    Maggs D; Shen L; Strobel S; Brown D; Kolterman O; Weyer C
    Metabolism; 2003 Dec; 52(12):1638-42. PubMed ID: 14669170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A fully artificial pancreas versus a hybrid artificial pancreas for type 1 diabetes: a single-centre, open-label, randomised controlled, crossover, non-inferiority trial.
    Tsoukas MA; Majdpour D; Yale JF; Fathi AE; Garfield N; Rutkowski J; Rene J; Legault L; Haidar A
    Lancet Digit Health; 2021 Nov; 3(11):e723-e732. PubMed ID: 34580055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pramlintide as an adjunct to insulin in patients with type 2 diabetes in a clinical practice setting reduced A1C, postprandial glucose excursions, and weight.
    Karl D; Philis-Tsimikas A; Darsow T; Lorenzi G; Kellmeyer T; Lutz K; Wang Y; Frias JP
    Diabetes Technol Ther; 2007 Apr; 9(2):191-9. PubMed ID: 17425446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pramlintide lowered glucose excursions and was well-tolerated in adolescents with type 1 diabetes: results from a randomized, single-blind, placebo-controlled, crossover study.
    Chase HP; Lutz K; Pencek R; Zhang B; Porter L
    J Pediatr; 2009 Sep; 155(3):369-73. PubMed ID: 19464026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes.
    Whitehouse F; Kruger DF; Fineman M; Shen L; Ruggles JA; Maggs DG; Weyer C; Kolterman OG
    Diabetes Care; 2002 Apr; 25(4):724-30. PubMed ID: 11919132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.